Search | Clinical Trials Finder

Conditions: Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
Interventions: AZLI, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 3 Months to 18 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 12
States / cities: San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more

Conditions: Diabetes Mellitus
Interventions: gamma-amino-butyric acid, Xylitol; Drug · Dietary Supplement
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 8 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Glioblastoma Multiforme
Interventions: arginine in powder form, Silica and cellulose placebo powder; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Fairfax, Virginia

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 75 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 62
States / cities: Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more

Conditions: Von Willebrand Diseases
Interventions: Wilate; Drug
Lead sponsor: Octapharma; Industry
Eligibility: 6 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Advanced Solid Tumors Cancer
Interventions: Livmoniplimab, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 21
States / cities: Springdale, Arkansas • Duarte, California • Irvine, California + 16 more

Conditions: Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions: Travelan, Placebo; Biological · Other
Lead sponsor: Immuron Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ADVANCED SOLID TUMORS
Interventions: PM01183; Drug
Lead sponsor: PharmaMar; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Age-related Macular Degeneration (AMD)
Interventions: Lutein-enriched-egg beverage (NWT-02), Placebo; Dietary Supplement
Lead sponsor: Newtricious R&D BV; Industry
Eligibility: 50 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration-resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer
Interventions: Testosterone cypionate, Nivolumab; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Baltimore, Maryland • Boston, Massachusetts

Conditions: Infections, Bacterial
Interventions: GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: placebo, 0.1 mg GSK2330672, 0.3 mg GSK2330672, 1 mg GSK2330672, 3 mg GSK2330672, 10 mg GSK2330672, 30 mg GSK2330672, 60 mg GSK2330672; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
Interventions: Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C; Dietary Supplement
Lead sponsor: Standard Process Inc.; Industry
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Pulmonary Arterial Hypertension
Interventions: GB002 (seralutinib), Generic Dry Powder Inhaler; Drug · Device
Lead sponsor: Gossamer Bio USA, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 15
States / cities: Sacramento, California • Santa Barbara, California • Jacksonville, Florida + 11 more

Conditions: Von Willebrand Disease
Interventions: Vonicog alfa, Antihemophilic Factor (Recombinant); Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: Up to 17 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 16
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Jacksonville, Florida + 12 more

Conditions: Infections, Bacterial
Interventions: GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Acute Myeloid Leukemia
Interventions: Gilteritinib, Idarubicin, Cytarabine, Daunorubicin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • Chicago, Illinois + 7 more

Conditions: Asthma
Interventions: formoterol, Dry Powder Inhaler (Twisthaler); Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 60 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ELLIPTA placebo DPI, DISKUS placebo DPI, HandiHaler placebo DPI, Inhaler preference questionnaires; Device · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 18
States / cities: Orlando, Florida • Natchitoches, Louisiana • Saint Charles, Missouri + 14 more

Conditions: L-theanine
Interventions: Theanine, Caffeine, Theanine-Caffeine Combination, Placebo; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Cystic Fibrosis
Interventions: TOBIpodhaler; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: FF, Placebo, Montelukast, Albuterol/Salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Little Rock, Arkansas • Alhambra, California • Costa Mesa, California + 8 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more

Search by objective public record fields.

Study of Aztreonam for Inhalation in Children With Cystic Fibrosis and New Infection of the Airways by Pseudomonas Aeruginosa Bacteria

Effect of GABA Supplementation in the Progression of Type 1 Diabetes in Children

Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme

12-week Efficacy of Indacaterol

Clinical Study to Investigate the Efficacy and Safety of Wilate During Prophylaxis in Previously Treated Patients With VWD

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Clinical Study to Assess the Efficacy of Once-daily IMM-124E (Travelan®) in a Controlled Human Infection Model.

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors

Intervention Trial in Early Age-related Macular Degeneration

COMbination of Bipolar Androgen Therapy and Nivolumab

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

First Time in Human Study Using GSK2330672

The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

A Study To Evaluate The Effects Of PF-05175157 In Healthy Volunteers

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Dose-response of Inhaled Formoterol Using Methacholine Challenge as a Bioassay

Comparative Study of ELLIPTA Dry Powder Inhaler (DPI) Versus DISKUS DPI Used With HandiHaler DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Theanine and Caffeine on Neurophysiology of Attention

Efficacy of TOBI Podhaler vs. Tobramycin Inhalation Solution

Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)